Open access
Sep 2026
Disitamab vedotin triggers ferroptosis to activate CD8+ T-cell antitumor immunity in HER2-expressing breast cancer
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is highly aggressive and is associated with poor prognosis after metastasis or recurrence. The development of anti-HER2 antibody–drug conjugates (ADCs) has markedly improved outcomes. Disitamab vedotin (RC48) is a novel anti-HER2 ADC that exhibi...
Ying-Ying Zhao, Chen-Wei Yuan, Qiong Wu et al.
· Journal of Experimental &... · 0 citations